Context Therapeutics, Inc.

As of June 18, 2025, the technical trend is bearish with mixed signals from indicators like the MACD and Bollinger Bands, while the OBV and Dow Theory show uncertainty.

Context Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of $51.78 million and a recent net profit loss of $5 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -30.37%.

As of Jun 18, Context Therapeutics, Inc. has a market capitalization of 51.78 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -27.63 million for the latest four quarters. As of December 2024, the company reported shareholder's funds of 95.27 million and total assets of 98.13 million.